Thyroid hormone and the skeleton
================================

Thyroid hormone (T3) is a major regulator of skeletal development. T3-actions are mainly mediated via TRα and TRβ nuclear receptors, which are alternatively spliced to produce multiple isoforms \[[@r55]\]. The inception and timing of TR expression is variable and occurs in tissue-specific patterns *in utero*, throughout development and in adulthood. Thus, TR expression is regulated in a temporo-spatial manner and, as a consequence, the ratios of expressed TR isoforms vary between individual tissues \[[@r55]; [@r2]\]. In the skeleton, TRα1 mRNA is expressed at 12-fold higher concentrations than TRβ1 \[[@r10]\]. TRα1, TRα2 and TRβ1 mRNAs and proteins have been identified in growth plate chondrocytes and osteoblasts at sites of endochondral and intramembranous ossification \[[@r61]; [@r73]; [@r75]\]. However, it is not known whether TRα and β isoforms are co-expressed in individual bone cells or whether discrete actions will eventually be ascribed to each isoform.

Resistance to thyroid hormone and mouse models
==============================================

RTH is an autosomal dominant condition characterized by reduced tissue sensitivity to thyroid hormones and disruption in the hypothalamic-pituitary-thyroid (HPT) axis leading to elevated levels of T3 and T4 together with inappropriately raised TSH concentrations. Affected individuals possess dominant-negative mutant TRβ proteins that interfere with the actions of wild-type TRs and disrupt T3-regulated gene transcription. The clinical features of RTH are variable and phenotypic differences occur between families with different mutations, between families that harbor an identical mutation, and between individuals of one family with an identical mutation \[[@r6]\]. An example of the phenotypic variability is the skeleton where a wide variety of abnormalities have been described \[[@r21]; [@r9]; [@r6]\].

We previously analyzed skeletal development in mice with a PV mutation targeted to the TRβ gene \[[@r10]\]. The PV mutation, derived from a patient with severe RTH and an affected skeletal phenotype \[[@r16]\], is a C-insertion at codon 448, which produces a frameshift of the 14 amino acids at the carboxyl-terminal of the TRβ gene \[[@r13]\]. The mutant protein does not bind T3, has no transactivation activity and is a potent dominant-negative antagonist. Heterozygous TRβ^PV/+^ mice mirror human RTH with circulating concentrations of T3, T4 and TSH increased 2-, 2.5- and 2.1-fold, respectively. Homozygous TRβ^PV/PV^ mice have very high levels of circulating T3, T4 and TSH, elevated 9-, 15- and 412-fold, respectively \[[@r13]\]. We demonstrated that homozygous TRβ^PV/PV^ mice displayed advanced endochondral and intramembranous ossification \[[@r10]\]. The expression of fibroblast growth factor receptor-1 (FGFR1), previously identified as a skeletal T3-target gene \[[@r12]\], was elevated in TRβ^PV^ mice indicating increased T3 signaling in the mutant skeleton. Heterozygous TRβ^PV/+^ mice demonstrated an intermediate phenotype. Taken together, the results suggested a phenotype of skeletal thyrotoxicosis, consistent with the hypothesis that elevated circulating thyroid hormone levels drive the thyrotoxic phenotype via increased stimulation of an intact TRα1 signaling pathway in bone.

To investigate this hypothesis and determine whether TRα1 is the predominant TR isoform in bone, we studied mice carrying the identical mutation targeted to TRα1 \[[@r11]\]. The mutant TRα1^PV^ protein is also a potent dominant-negative antagonist capable of interfering with the activities of wild-type TRα1 and TRβ. The homozygous mutation was lethal and heterozygous TRα1^PV/+^ mice displayed only mild thyroid failure, with circulating T3 and T4 levels in the euthyroid range. The observed minor increase in T3 (1.15 fold) and no change in T4 \[[@r14]\] was consistent with other mice harboring dominant-negative RTH mutations in TRα1 \[[@r15]; [@r7]\]. Heterozygous TRα1^PV/+^ mice were dwarfs, exhibiting severely delayed endochondral and intramembranous ossification and postnatal growth retardation. In contrast to TRβ^PV^ mice, FGFR1 expression was reduced in TRα1^PV/+^ mutants, demonstrating impaired skeletal T3 signaling and skeletal hypothyroidism in TRα1^PV/+^ mice, consistent with significant levels of expressed mutant TRα1^PV^ in bone that impairs the activities of wild-type TRα1 and β proteins. Our studies also indicated that the skeletal consequences of the PV mutation, when affecting either TRα1 or TRβ, result from dysregulated local GH/IGF-1 signaling in the growth plate, suggesting this signaling pathway lies downstream of TRα1 during bone development.

Thus, TRα1^PV/+^ mice display skeletal hypothyroidism despite the presence of biochemical euthyroidism \[[@r11]\] and, in contrast, TRβ^PV^ mice have severe RTH but a phenotype of skeletal thyrotoxicosis \[[@r10]\]. Our studies indicate this paradox results from the differing effects of the PV mutations at the level of the HPT axis and in the skeleton ([Figure 1](#fig1){ref-type="fig"}). In the hypothalamus and pituitary, TRβ is the predominant isoform. Mutation of TRβ has been shown to produce RTH with elevated thyroid hormone concentrations and impaired feedback regulation of TRH and TSH. Thus, TRβ is critical for the determination of both the set-point of the HPT axis and the levels of circulating thyroid hormones \[[@r59]; [@r60]; [@r66]; [@r57]; [@r70]; [@r71]; [@r13]\]. In TRα^0/0^β^-/-^ mice, TSH elevation is more severe than in TRβ^-/-^ animals suggesting the TRα gene may also play a role in set-point regulation \[[@r69]\]. However, this role is likely to be compensatory and, in the physiological setting, TRα1 is much less important in HPT axis regulation. Indeed, mutation of the TRα locus has been shown to amplify the regulation of TRH in the hypothalamus but not interfere with TSH feedback regulation, circulating T4 and T3 levels, or affect pituitary function \[[@r66]; [@r69]; [@r14]; [@r15]; [@r7]\]. Thus, in TRβ^PV^ mice, the pituitary displays tissue hypothyroidism and in TRα1^PV/+^ animals severe growth retardation occurs despite normal pituitary function. In contrast, our studies establish that TRα1 is the predominant isoform in bone \[[@r11]; [@r10]; [@r12]\]. Thus, in PV mutant mice, the hyperthyroid TRβ^PV/PV^ skeleton results from increased TRα1 activity stimulated by thyrotoxic circulating hormone levels resulting from HPT axis dysregulation. The phenotype is less severe in TRβ^PV/+^ heterozygous animals because peripheral hormone concentrations are less markedly elevated. In the TRα1^PV/+^ skeleton, impaired TRα1 function determines the hypothyroid skeletal phenotype observed ([Figure 2](#fig2){ref-type="fig"}).

Implications of skeletal observations
=====================================

Phenotypic variability is a characteristic of human RTH and it is possible this may result from a range of individual RTH mutations that interact with genetic background factors leading to the production of mutant TRβ proteins with unique properties. Each mutation may affect T3 binding affinity or cofactor interactions in a specific manner resulting in variable dysregulation of the HPT axis and a spectrum of dominant negative activity. In the physiological setting, the TRβ mutation may act as a rheostat to determine the magnitude of resistance and the relationship of TSH to T4 and T3 levels. For instance, if an RTH mutation had a minimal effect on T3 binding affinity, resistance to negative feedback regulation of TSH may be overcome easily resulting in a minor change in circulating thyroid hormone levels. In contrast, if a mutation severely impaired T3 binding, as in the case of PV, TSH negative feedback regulation would be abolished and TSH levels profoundly increased irrespective of T4 and T3 levels. It is also likely that the dominant negative properties of each RTH mutation in each target tissue, combined with the differing TR isoform expression ratios in individual tissues, modifies the phenotype and provides a potential explanation for the heterogeneity observed in RTH.

Our analysis of TRα1^PV/+^ and TRβ^PV^ mutant mice has provided a new understanding of the complex relationship between central pituitary thyroid status and peripheral skeletal thyroid status that arises because the pituitary gland is a TRβ target tissue, whereas bone is a TRα1 target organ. Numerous groups have demonstrated differential TR isoform specific actions in individual tissues suggesting the hypothesis that tissue-specific responses to thyroid hormones result from differential TR expression patterns. Thus, the liver, ear and retina have also been identified as TRβ target tissues whilst the heart, like bone, is a TRα1 target organ \[[@r65]; [@r68]\]. Our studies in liver and heart from TRβ^PV^ mice further indicated that tissue-specific expression of TR isoforms dictates the dominant negative activity of the mutant receptor \[[@r17]\]. The new studies in bone refine the hypothesis further and suggest the model can be extended to analyze the relationship between central and peripheral thyroid status in any T3-target tissue, depending on whether the peripheral tissue in question is predominantly responsive to TRα1 or TRβ.

Evidence from genetically modified mice supports this contention. For example, in the heart, in which TRα1 predominates, TRβ^-/-^ mice exhibit features of thyrotoxicosis including tachycardia and increased expression of the cyclic nucleotide-gated channels HCN2 and HCN4, which are cardiac T3-target genes \[[@r18]\]. In contrast, in TRα1^-/-^ mice, features of hypothyroidism have been reported including bradycardia and reduced body temperature \[[@r19]\]. Heart glucose utilization was reduced in TRα1^PV/+^ mice and increased in TRβ^PV/PV^ animals and these opposite effects on cardiac energy metabolism are consistent with bradycardia associated with hypothyroidism and tachycardia observed in hyperthyroidism and RTH \[[@r67]\]. In the reproductive system, sertoli cell development is predominantly mediated through TRα1. TRα-null mice exhibited hypothyroid features including increased sertoli cell number and testis weight while TRβ^-/-^ animals maintained normal sertoli cell responsiveness to T3 \[[@r72]\]. In the liver, a TRβ-predominant tissue, T3 influences cholesterol metabolism via regulation of cholesterol 7α-hydroxylase (CYP7A). TRβ^-/-^ mice exhibit features of hypothyroidism with loss of hepatic T3-responsiveness, whereas normal CYP7A activity is observed in TRα1 deficient mice \[[@r20]\]. These insights into TR isoform-specific actions of T3 have important clinical implications. Thus, development of TR isoform-specific agonists and antagonists is likely to provide new therapeutic options for the treatment of diseases such as hypercholesterolemia, cardiac arrhythmias, growth disorders and osteoporosis \[[@r64]\].
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![Hypothalamic-pituitary-thyroid (HPT) axis, tissue distribution of TRs and predominant TR-isoform responsiveness of selective T3-target tissues\
Serum concentrations of the thyroid hormones (T4 and T3) are maintained by a negative feedback system involving the hypothalamus, the pituitary and the thyroid gland. The circulating T3 and T4 exert direct negative feedback control on both TRH and TSH secretion, predominantly via regulation by TRβ. TSH itself inhibits the secretion of TRH. Relative TR distribution in individual tissues is highlighted; blue, TRβ predominant tissue; green, mixed; yellow, TRα1 predominant tissue.](nrs04011.f1){#fig1}

![Proposed mechanism for TRα1^PV/+^ and mutant TRβ^PV^ mutant mice\
**TRα1^PV/+^:** In a TRβ predominant tissue, e.g. pituitary, the low levels of PV mutant receptor are unable to interfere with the actions of wild-type TRβ. In contrast, in a TRα1 predominant tissue, e.g. bone, the increased levels of dominant negative mutant receptor interfere with the actions of the wild-type receptors and impair the expression of T3-target genes. As a consequence, in TRα1^PV/+^ mutant mice, TRβ predominant tissues exhibit a euthyroid phenotype and TRα1 predominant tissues display a hypothyroid phenotype. **TRβ^PV/+^ and TRβ^PV/PV^:** In the TRβ predominant pituitary, there is a high level of TRβ expression relative to TRα1. Consequently, there are increasing levels of mutant and either low levels or no wild type TRβ in TRβ^PV/+^ and TRβ^PV/PV^ tissues, respectively. In TRα1 predominant bone, the situation differs because levels of TRβ are low compared to TRα1. In both TRβ^PV/+^ and TRβ^PV/PV^ mice, the low levels of mutant receptor are unable to interfere with the action of TRα1. Thus, in TRβ^PV^ mice, where the TRβ mutant acts as a rheostat and disrupts HPT axis regulation, TRβ predominant tissues display a hypothyroid phenotype with impaired expression of T3-target genes. TRα1 predominant tissues appear hyperthyroid in response to increased TRα1 activity that is stimulated by thyrotoxic circulating hormone levels resulting from impaired HPT axis regulation. The phenotype is less severe in TRβ^PV/+^ heterozygous animals because peripheral hormone concentrations are less markedly elevated. A range of secondary mediators are included that have recently been shown to be targets of T3 action \[Barnard et al., 2005; Bassett et al., 2006; O\'Shea P et al., 2005; Stevens et al., 2003; Stevens et al., 2000\].](nrs04011.f2){#fig2}
